Legius syndrome, caused by SPRED1 mutations, has phenotypic overlap with neurofibromatosis type 1 (NF1) without tumorigenic manifestations. Patients fulfilling the National Institutes of Health (NIH) diagnostic criteria for NF1 were enrolled at the University of Utah NF Clinic, and SPRED1 mutation analysis was performed to identify the frequency of Legius syndrome within an NF1 clinic population. SPRED1 sequencing was performed on 151 individuals with the clinical diagnosis of NF1, and 2 individuals (1.3%) were found to have novel SPRED1 mutations, p.R18X and p.Q194X. The phenotypes for the 2 individuals with SPRED1 mutations included altered pigmentation without tumorigenesis. A specific SPRED1 haplotype allele was identified in 27 individuals. The frequency of SPRED1 mutations in patients meeting diagnostic criteria for NF1 in a hospital-based clinic is 1% to 2%. The likelihood an individual is harboring a SPRED1 mutation increases with age if multiple, nonpigmentary NF1 findings are absent. Legius syndrome patients may benefit from altered medical surveillance.
Neurofibromatosis type 1 (NF1) is a relatively common autosomal dominant disorder occurring in 1 of every 3000 births. NF1 shows complete penetrance by adulthood; yet, there is a high degree of variable clinical expressivity, both interfamilial and intrafamilial variability. Cardinal clinical manifestations are café-au-lait spots and neurofibromas, and other features include Lisch nodules, optic pathway gliomas, malignant peripheral nerve sheath tumors (MPNSTs), learning disorders, and bone abnormalities. While the clinical diagnosis for NF1 is based on National Institutes of Health (NIH) clinical diagnostic criteria, other disorders have overlapping phenotypes with NF1. The overlapping phenotype can potentially complicate diagnostic evaluations and lead to medically inappropriate screening protocols. Examples of these disorders include Noonan syndrome, LEOPARD syndrome, cardiofaciocutaneous (CFC) syndrome, Costello syndrome, 1 and Legius syndrome. [2] [3] [4] [5] The causative genes for all of these disorders encode proteins within the Ras-MAPK signaling pathway.
Legius syndrome, originally termed ''neurofibromatosis type 1-like syndrome,'' is caused by SPRED1 mutations on chromosome 15q13.2. 2 Individuals with SPRED1 mutations frequently fulfill the NIH diagnostic criteria for NF1 based on pigmentary manifestations of café-au-lait spots and distinctive freckling patterns. [2] [3] [4] This overlapping phenotype is likely due to increased Ras signal propagation caused by inactivating SPRED1 mutations. Normally, SPRED1 protein binds to Ras and blocks phosphorylation of Raf, which diminishes downstream ERK activation. 2 The phenotype due to SPRED1 mutations as described by Brems et al includes café-au-lait spots (98%), freckling (30%), and macrocephaly of 97th percentile (42%). 2 Of the 44 reported cases (age range, 1-66 years) in these 5 families, Brems et al reported 14 patients with lipomas, 6 with learning problems, 5 with Noonan-like facial features, 3 with depigmented spots, 2 with attention deficit and hyperactivity disorder, and 3 with pectus excavatum. Neurofibromas, Lisch nodules, optic pathway tumors, or malignant tumors were not identified. 2 Three additional studies by Pasmant, 3 Spurlock, 4 and Messiaen 5 reported similar phenotypes in patients with SPRED1 mutations. Spurlock et al tested 85 unrelated cases without detectable NF1 mutations or neurofibromas and identified 6 individuals with SPRED1 mutations. 4 They then screened family members of these 6 cases and identified a total of 12 individuals with SPRED1 mutations. All had café-au-lait macules, approximately two thirds had intertriginous freckling, and there was no report of learning problems, Lisch nodules, neurofibromas, or optic gliomas. Pasmant et al tested 61 index cases with the clinical diagnosis of NF1 without an identifiable NF1 mutation and found 5 individuals with SPRED1 mutations. 3 They also screened additional family members from these 5 cases and identified a total of 18 individuals from 5 families with SPRED1 mutations. From the report, 3 9 of the 18 individuals with SPRED1 mutations fulfilled the NF1 diagnostic criteria, assuming that individuals in their age categories of 0 to 4, 5 to 9, and 10 to 14 years are not postpubertal. This assumption is important given that the NIH diagnostic criterion for café-au-lait macules states ''six or more café-au-lait macules over 5mm in diameter in prepubertal individuals and over 15mm in greatest diameter in postpubertal individuals.'' 6, 7 All 18 individuals had at least 2 café-au-lait macules, 72% had intertriginous freckling, 2 had lipomas, 4 had learning disabilities, 1 had epilepsy, 1 had monoblastic acute leukemia, and none had Lisch nodules, neurofibromas, or optic gliomas. Messiaen et al reported a large cohort of individuals who were tested for SPRED1 mutations after testing negative for NF1 mutations, and none were reported to have any tumorigenic manifestations associated with NF1. 5 A comparison of some of the clinical features of SPRED1 and NF1 is summarized in Table 1 . It appears from the reports to date that patients with Legius syndrome do not develop some of the more morbid complications seen with NF1, particularly tumor formation, and an altered health care management plan may be appropriate.
Previous studies 2-5 evaluated cohorts of individuals with clinical features of NF1 who did not have identifiable NF1 mutations. Approximately 5% of patients who meet the NIH clinical diagnostic criteria for NF1 do not have an identifiable NF1 mutation by exhaustive mutation analysis. 8 Our aim was to identify the frequency of SPRED1 mutations in individuals with a clinical diagnosis of NF1 within an unselected Neurofibromatosis Clinic population.
Patients and Methods

NF1 Patient Phenotyping
Individuals meeting NIH clinical diagnostic criteria for NF1 evaluated at the University of Utah Neurofibromatosis Clinic were offered enrollment. Prior to SPRED1 sequencing, a detailed physical examination and review of medical records were performed on all NF1 individuals by one physician investigator between 2002 and 2009 (D.S.). A standardized NF1 history and examination form created for use for the University of Utah NF1 Registry, and modeled after information requested by the Children's Tumor Foundation (formerly National Neurofibromatosis Foundation) International Database, 9 was modified and used to document the phenotype. For purposes of this study, probands were defined as the individual within a family who was first enrolled. Approval by the Institutional Review Board at the University of Utah was obtained.
SPRED1 Gene Sequencing
Primer sets were designed for the coding regions and intron/exon boundaries of SPRED1. These were designed using LightScanner Primer Design software by Idaho Technology Inc (Salt Lake City, Utah). Selected primer sets were supplied by Integrated DNA Technologies (Coralville, Iowa). Primer sequences are available upon request. Genomic DNAs were isolated from peripheral blood using the Puregene DNA extraction kit (Gentra Systems Inc, Minneapolis, Minnesota). Each patient sample was amplified by polymerase chain reaction (PCR). All post-PCR products were checked for the appropriate band size using capillary electrophoresis by the Qiagen eGene (Germantown, Maryland). PCR primers were then degraded using exoSAP-IT (USB Corporation, Cleveland, Ohio), after which bidirectional Sanger sequencing was performed followed by Sephadex clean-up (GE Healthcare Life Sciences, Piscataway, New Jersey). Products were then assessed by an ABI 3730 analyzer (Applied Biosystems Inc, Foster City, California). All sequence analysis was performed using Mutation Surveyor software (SoftGenetics, State College, Pennsylvania) and compared with the GenBank reference sequence NC_000015. All amplicons were sequenced in both the forward and reverse directions.
Control Population Sample
Normal control population allele studies were performed using DNA from 32 anonymous healthy individuals from the ARUP clinical laboratory (Salt Lake City, Utah). These samples were only tested for the specific exons required to identify the SPRED1 haplotype of interest.
Results
The SPRED1 gene was sequenced for 151 individuals with the clinical diagnosis of NF1. Demographics are described in Table 2 . Within this cohort, 2 prepubertal, unrelated individuals with novel SPRED1 mutations, p.R18X and p.Q194X, were identified. The first individual had a mutation in SPRED1 with a C>T nucleotide substitution at position c.52, generating a premature stop codon at p.18 (p.R18X). This patient's mutation was confirmed on a clinical basis by the University of Alabama Medical Genomics Laboratory (Birmingham, Alabama). The observed phenotype for this individual, age 12 years, included 10 to 20 café-au-lait spots, subtle inguinal and axillary freckling, learning disabilities requiring intervention, and no neurofibromas ( Figure 1A and 1B). His occipital frontal circumference (OFC) was at the 95th percentile, weight was at the 75th percentile, and height was at the 25th percentile. He was reported to have a single Lisch nodule by slit lamp examination, which was clinically reported by an ophthalmologist at an outside institution over multiple evaluations. Given that no other individual with a SPRED1 mutation has been reported to have Lisch nodules, the patient was evaluated at the University of Utah by one of the authors (D.D.), a pediatric ophthalmologist who follows a large number of individuals with NF1, for further investigation of the ophthalmologic findings. The patient did not have classic Lisch nodules; however, he had an unusual pattern of iris pigmentation with multiple iris nevi of varying size (Figure 2A) and abnormally large and wide iris crypts ( Figure 2B ).
The second individual had a mutation in SPRED1 with a C>T nucleotide substitution at position c.580, resulting in a premature stop codon at p.194 (p.Q194X). The phenotype for this individual, age 10 years, included more than 10 café-aulait spots, axillary and groin freckling, learning disabilities requiring intervention, and no neurofibromas ( Figure 1C and 1D). His OFC was >98th percentile, height was at the 95th percentile, and weight was >98th percentile. Ophthalmologic examination at 7 years of age showed no Lisch nodules; however, this individual was reported by a pediatric ophthalmologist at the University of Utah to have ''the sort of very convoluted brown iris making detection of Lisch nodules very difficult.'' Demographic and phenotypic information for the clinic cohort was used for comparison between individuals meeting the NIH diagnostic criteria for NF1 with and without a SPRED1 mutation. Based on the presence or absence of a specific finding or combination of specific findings, the likelihood of having a SPRED1 mutation is outlined in Figure 3 . Within our clinic cohort of individuals fulfilling NIH diagnostic criteria for NF1, we identified 1.32% with SPRED1 mutations and 2.60% if selected for only sporadic cases. Selecting for those individuals who lacked Lisch nodules, optic gliomas, neurofibromas, long bone dysplasia and sphenoid wing dysplasia, or a family history, this percentage increases to 20%. This percentage increases further with age to 50% for those 10 years or older.
In establishing an assay to identify SPRED1 mutations, we identified a common haplotype allele matching GenBank sequence NG_008980. This haplotype allele (SPRED1 2 ) is defined by 4 single nucleotide polymorphisms (SNPs), differing from the more common SPRED1 1 reference sequence NC_000015. The SPRED1 2 allele was identified in 27 of the 151 individuals sequenced (17.9%). Twenty-five NF1 individuals were heterozygous for SPRED1 2 while 2 patients were homozygous. The overall SPRED1 2 allele frequency was 9.6%. When only probands are used to calculate the haplotype allele frequency (excluding the affected related individuals), 25 of 127 individuals carry the SPRED1 2 haplotype allele (19.7%; allele frequency, 10.6%). Two of the single nucleotide polymorphisms were found within exons and caused synonymous changes. The first exonic SNP is located in exon 4 (c.291A>G; p.K97K), and the second exonic SNP is located in exon 8 (c.1044C>T; p.V348V). Both intronic SNPs are located within the intronic region between exons 5 and 6 (c.424-8A>C and c.424-98C>T). Neither of these 2 intronic SNPs is predicted to cause splice site alterations. 10 None of these 4 SNPs were seen as an isolated event in any of the 151 patients sequenced, indicating that this haplotype block is in high disequilibrium. The allele frequency in our unselected normal population was slightly decreased from the NF1 cohort (12.5% [4/32, P ¼ .049]). No SPRED1 2 allele homozygotes were identified in the unselected population. The overall allele frequency was 6.3% (4/64 alleles). The difference in allele frequency between the NF1 probands only versus the unselected control population is statistically significant (P ¼ .02). Demographic data were not available for the normal population.
Discussion
The overlap of disease phenotype within the disorders of the Ras-MAPK pathway is well established. [1] [2] [3] [4] [5] [11] [12] [13] [14] [15] [16] [17] One of the most common Ras-MAPK pathway disorders is NF1. In individuals fulfilling the NIH diagnostic criteria for NF1, 95% have identifiable mutations of the NF1 gene. 8 Thus, NF1 mutations are not identified in approximately 5% of patients who meet NIH clinical diagnostic criteria for NF1. If diagnostic criteria are met solely by pigmentary findings (with or without a first-degree relative), a proportion of these individuals could have Legius syndrome with mutations in SPRED1. It is also possible that the remaining individuals have an NF1 mutation that is undetectable by current methods, a different overlapping Ras pathway disorder, or mutations in other unknown genes.
There are several reports of families with isolated, multiple café-au-lait macules inherited in an autosomal dominant pattern. [18] [19] [20] [21] [22] Several of these families showed no linkage to the NF1 locus, 18, 20, 22 and one family's phenotype did not segregate with SPRED1. 20 This suggests that other unknown genes can result in a pigmentary phenotype similar to Legius syndrome and NF1. Our data show that 1.3% of individuals who meet the clinical diagnostic criteria for NF1 and seeking medical care at . Each separate table analyzes only those individuals for whom data for the specific neurofibromatosis type 1 (NF1) feature indicated by each table ''title'' are available. This ''n'' value is located in the upper left corner of each table. The clinic cohort includes all patients regardless of inheritance pattern. The nonfamilial cohort only analyzes those patients who were known to be sporadic. Those individuals for whom the title NF1 feature is absent are identified as either SPRED1 mutation positive or SPRED1 mutation negative. These data were compiled using each individual's last office visit NF1 intake form. Only those patients with positive results or negative results were used for analysis. Those patients for whom data were unavailable for a specific finding of interest were excluded from analysis. Long bone dysplasia includes long bone bowing and/or pseudarthrosis. an NF clinic have SPRED1 mutations. This percentage increases if the cohort is stratified to eliminate those with an affected parent, an optic pathway tumor, bona fide Lisch nodules, neurofibromata, long bone dysplasia, or sphenoid wing dysplasia. In this circumstance, the percentage of patients with SPRED1 mutations is 20%. Because of the age-related penetrance of nonpigmentary manifestations of NF1, as an individual's age increases, the absence of certain characteristic features of NF1 becomes more predictive of Legius syndrome. For individuals 10 years of age or older who do not have other NF1 features, yet fulfill diagnostic criteria for NF1 by pigmentary features, 50% harbor a SPRED1 mutation (Figure 3 ). While the chance of having both an NF1 mutation and a SPRED1 mutation is possible, co-occurrences of 2 rare disorders are extremely infrequent. 23 The phenotypes of the 2 individuals with SPRED1 mutations were consistent with the previous reports to date [2] [3] [4] [5] (Table 1) , including café-au-lait spots, intertriginous freckling, learning disabilities, and no neurofibromas. Both children were older than 10 years of age and had not yet developed neurofibromas. One patient with a SPRED1 mutation was initially reported to have a single identified Lisch nodule, although a subsequent evaluation did not confirm the findings. To date, there are no reported cases of individuals with SPRED1 mutations who have Lisch nodules, including those adults (>18 years old) identified by previous authors. [2] [3] [4] [5] As shown in Figure 2 , it is possible that individuals with Legius syndrome have increased pigment deposits in the iris, which may lead some physicians to confuse increased pigment with Lisch nodules, especially if one does not frequently evaluate patients with NF1. It is important to accurately diagnose Lisch nodules in individuals with isolated café-au-lait macules and/or intertriginous freckling, as the presence of Lisch nodules would impact the delineation of Legius syndrome versus NF1, and the diagnosis could subsequently change medical management and counseling. Because only a small number of Legius syndrome patients have been reported to date, it may be that a small percentage of patients may have increased pigment deposits or other iris findings. Further investigation is necessary to determine the degree of association and types of ocular abnormalities for individuals with SPRED1 mutations. The absence of a Lisch nodule in the above reported patient is consistent with Legius syndrome.
The phenotype of Legius syndrome is currently based on a cross-sectional phenotype of a small number of patients. [2] [3] [4] [5] The clinical manifestations of Legius syndrome will continue to become better defined with the identification of more individuals. Long-term studies will be required to confirm the current suggested phenotype and establish the lifetime risk of tumorigenesis and whether it is increased compared with the general population. Within our cohort, the phenotype primarily consists of altered pigmentary patterns and learning disorders, as demonstrated in previously reported cases. [2] [3] [4] [5] This is also consistent with the relative lack of manifestations of tumorigenesis in Legius syndrome. Pasmant et al 2 identified one SPRED1 mutation-positive patient with acute myelogenous leukemia.
While no second hit in SPRED1 could be identified in this patient, the authors could not definitively discern causality in relation to Legius syndrome. Our data support the lack of tumorigenesis in Legius syndrome.
An altered management plan may be appropriate for young individuals fulfilling the pigmentary diagnostic criteria for NF1 who have SPRED1 mutations rather than NF1 mutations. Because the absence of characteristic NF1 findings appears consistent across multiple studies, 2-5 this absence may help identify individuals with SPRED1 mutations. For those patients meeting NIH diagnostic criteria for NF1 based on pigmentary findings alone, the likelihood of an individual having a SPRED1 mutation increases as multiple, additional characteristic NF1 findings are absent ( Figure 3 ) with increasing age. However, the possibility of an individual mildly affected with NF1 or NF1 mosaicism must always be considered.
A common SPRED1 haplotype allele was identified in 17.9% of our NF1 cohort (allele frequency of 9.6%), which is significantly more frequent than the 12.5% of an unselected population (allele frequency of 6.3%; P ¼ .049). However, because demographic data for the unselected population are not available, ethnicity may be a confounding factor. In addition, it is possible that this is a founder effect within the Utah population. SPRED1 sequence variants could potentially modify the NF1 phenotype, and future studies will be important in examining the role of the SPRED1 haplotypes on the clinical manifestations in individuals with NF1.
Previous reports have shown that many individuals with SPRED1 mutations do not meet the NIH diagnostic criteria for NF1. [2] [3] [4] [5] Messiaen et al 5 analyzed individuals reported to meet NIH diagnostic criteria within their cohort of NF1-negative individuals and found that 1.9% of these individuals had SPRED1 mutations similar to the frequency we identified in our NF clinic. Given that our cohort only included individuals who fulfilled the NIH diagnostic criteria, the incidence of SPRED1 mutations in individuals without the clinical diagnosis of NF1 cannot be determined from our results. There is also a potential bias in this study, as the NF1 Clinic is staffed primarily by pediatricians at a tertiary children's hospital; thus, the cohort is primarily a pediatric population.
In summary, 1% to 2% of patients meeting NIH clinical diagnostic criteria for NF1 in a hospital-based clinic harbor SPRED1 mutations. Patients who fulfill only the pigmentary component of the NF1 diagnostic criteria are more likely to have a SPRED1 mutation, especially at an older age. Patients with SPRED1 mutations may require altered medical surveillance, based on the current Legius syndrome phenotype showing altered pigmentation with a lack of tumorigenesis.
